The estimated Net Worth of Kim Caple is at least $428 Тысяча dollars as of 14 July 2024. Kim Caple owns over 440 units of Castle Biosciences stock worth over $427,624 and over the last 3 years Kim sold CSTL stock worth over $0.
Kim has made over 5 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Kim exercised 440 units of CSTL stock worth $13,653 on 14 July 2024.
The largest trade Kim's ever made was exercising 8,636 units of Castle Biosciences stock on 25 May 2024 worth over $267,975. On average, Kim trades about 1,531 units every 81 days since 2021. As of 14 July 2024 Kim still owns at least 13,781 units of Castle Biosciences stock.
You can see the complete history of Kim Caple stock trades at the bottom of the page.
Kim's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.
Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold и Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: